No association between fear of hypoglycemia and blood glucose variability in type 1 diabetes: The cross-sectional VARDIA study

In type 1 diabetes (T1D), treatment efficacy is limited by the unpredictability of blood glucose results and glycemic variability (GV). Fear of Hypoglycemia (FOH) remains a major brake for insulin treatment optimization. We aimed to assess the association of GV with FOH in participants with T1D in a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of diabetes and its complications Ročník 33; číslo 8; s. 554 - 560
Hlavní autoři: Saulnier, Pierre Jean, Briet, Claire, Gand, Elise, Chaillous, Lucy, Dubois, Severine, Bonnet, Fabrice, Leguerrier, Anne Marie, Fradet, Gérard, Delcourt Crespin, Ingrid, Kerlan, Veronique, Gouet, Didier, Perlemoine, Caroline, Ducluzeau, Pierre Henri, Pichelin, Matthieu, Wargny, Matthieu, Gonder-Frederick, Linda, Ragot, Stephanie, Hadjadj, Samy, Cariou, Bertrand
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Inc 01.08.2019
Elsevier Limited
Elsevier
Témata:
Animal biology
Blood pressure
Cardiovascular disease
Cellular Biology
Diabetes
Diaries
Epidemiology
Food and Nutrition
Glucose
Hypoglycemia
Insulin
Insulin therapy
Life Sciences
Oxidative stress
Pharmaceutical sciences
Population
Psychological aspects
Quality of life
Questionnaires
Self-management
France
Psychological aspects
Self-management
Insulin therapy
Hypoglycemia
Epidemiology
ISSN:1056-8727, 1873-460X, 1873-460X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In type 1 diabetes (T1D), treatment efficacy is limited by the unpredictability of blood glucose results and glycemic variability (GV). Fear of Hypoglycemia (FOH) remains a major brake for insulin treatment optimization. We aimed to assess the association of GV with FOH in participants with T1D in an observational cross-sectional study performed in 9 French Diabetes Centres (NCT02790060). Participants were T1D for ≥5 years, aged 18–75 years, on stable insulin therapy for ≥3 months. The coefficient of variation (CV) of blood glucose and mean amplitude of glycemic excursions (MAGE) were used to assess GV from 7-point self-monitoring of blood glucose (SMBG). FOH was assessed using the validated French version of the Hypoglycemia Fear Survey-II (HFS-II) questionnaire. Among a total of 570 recruited participants, 298 were suitable for analysis: 46% women, 58% on continuous subcutaneous insulin infusion [CSII], mean age 49 ± 16 years, HbA1c 7.5 ± 0.9%, HFS-II score 67 ± 18 and 12% with recent history of severe hypoglycemia during the previous 6 months, mean CV 39.8 ± 9.7% and MAGE 119 ± 42 mg/dL. CV and MAGE did not significantly correlate with HFS-II score (R = −0.05;P = 0.457 and R = 0.08;P = 0.170). Participants with severe hypoglycemia in the previous 6 months had higher HFS scores. Participants with higher HFS scores presented more hypoglycemias during follow-up. FOH as determined using the HFS-II questionnaire was not associated with 7-point SMBG variability in participants with T1D, but was associated with a positive history of severe hypoglycemia. Higher FOH was associated with higher frequency of hypoglycemia during follow-up.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:1056-8727
1873-460X
1873-460X
DOI:10.1016/j.jdiacomp.2019.05.003